Zobrazeno 1 - 7
of 7
pro vyhledávání: '"M M, Bilimoria"'
Autor:
R M, O'Regan, A, Cisneros, G M, England, J I, MacGregor, H D, Muenzner, V J, Assikis, M M, Bilimoria, M, Piette, Y P, Dragan, H C, Pitot, R, Chatterton, V C, Jordan
Publikováno v:
JNCI Journal of the National Cancer Institute. 90:1552-1558
Background Tamoxifen has been shown to promote the growth of human endometrial tumors implanted in athymic mice, and it has been associated with a twofold to threefold increase in endometrial cancer. Toremifene, a chlorinated derivative of tamoxifen,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5113053f0e2b383e004dfd92452299a3
https://doi.org/10.1093/jnci/90.20.1552
https://doi.org/10.1093/jnci/90.20.1552
Autor:
Yeung-Chul Mun, Jeffrey E. Lee, Peter W.T. Pisters, Douglas B. Evans, Janice N. Cormier, M M Bilimoria
Publikováno v:
The British journal of surgery. 90(2)
Background Although much is known about the long-term outcome of patients undergoing left (distal) pancreatectomy for malignancy, comparatively little is known about the optimal management strategy for the residual transected pancreatic parenchyma an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::71d523153e2868b9d685accf7ff309af
https://pubmed.ncbi.nlm.nih.gov/12555295
https://pubmed.ncbi.nlm.nih.gov/12555295
Autor:
M M, Bilimoria, V C, Jordan
Publikováno v:
Cancer treatment and research. 94
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::3f77218a87826cc49010394521530d82
https://pubmed.ncbi.nlm.nih.gov/9587688
https://pubmed.ncbi.nlm.nih.gov/9587688
Autor:
M M, Bilimoria, V C, Jordan
Publikováno v:
Seminars in surgical oncology. 12(5)
One hundred years ago ovarian ablation was shown to be an effective treatment for advanced breast cancer in premenopausal women. Since that time many different treatment modalities have been advocated to improve patient survival. The value of adjuvan
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::d2ea87a3b5d592d385c78970ef7c27d0
https://pubmed.ncbi.nlm.nih.gov/8873322
https://pubmed.ncbi.nlm.nih.gov/8873322
Publikováno v:
The cancer journal from Scientific American. 2(3)
Toxifen, a nonsteroidal antiestrogen, is currently the most widely used adjuvant therapy for the treatment of breast cancer. Though the efficacy of tamoxifen has been well documented in clinical trials, the certainty over the duration of therapy is l
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::d7b92fb5f1dc139a22f581b3a5888e1e
https://pubmed.ncbi.nlm.nih.gov/9166514
https://pubmed.ncbi.nlm.nih.gov/9166514
Publikováno v:
Journal of Clinical Oncology. 29:312-312
312 Background: Gemcitabine and 5-fluorouracil (5-FU) represent the mainstay of chemotherapeutic options for pancreatic cancer. Currently, approximately 40% of patients with pancreatic cancer receive chemotherapy. Relapse is common after resection an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c3878ed18c4a8c1118fa1ac799a4c96a
https://doi.org/10.1200/jco.2011.29.4_suppl.312
https://doi.org/10.1200/jco.2011.29.4_suppl.312
Publikováno v:
Journal of Clinical Oncology. 29:229-229
229 Background: Gemcitabine and 5-fluorouracil (5-FU) with or without oxaliplatin are used to manage advanced or recurrent pancreatic cancer. Options are limited for patients who do not respond to these agents. This study determined the pattern of re
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::478172f50500c261afd260cf860c4550
https://doi.org/10.1200/jco.2011.29.4_suppl.229
https://doi.org/10.1200/jco.2011.29.4_suppl.229